Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F10%3A00103156" target="_blank" >RIV/00843989:_____/10:00103156 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2010/731426" target="_blank" >http://dx.doi.org/10.1155/2010/731426</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2010/731426" target="_blank" >10.1155/2010/731426</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation

Popis výsledku v původním jazyce

In a multicenter trial, renal transplant recipients were randomized to tacrolimus with fixed-dose sirolimus (Tac/SRL, N = 318) or tacrolimus with MMF (Tac/MMF, N = 316). Targeted tacrolimus trough levels were lower in the Tac/SRL group after day 14. Theprimary endpoint was renal function at 6 months using creatinine clearance (Cockcroft-Gault) and was comparable at 66.4?mL/min (SE 1.4) with Tac/SRL and at 65.2mL/min (SE 1.3) with Tac/MMF (completers). Biopsy-confirmed acute rejection was 15.1% (Tac/SRL) and 12.3% (Tac/MMF). In both groups, graft survival was 93% and patient survival was 99.0%. Premature withdrawal due to an adverse event was twice as high in the Tac/SRL group, 15.1% versus 6.3%. Hypercholesterolemia incidence was higher with Tac/SRL (P < .05) while CMV, leukopenia, and diarrhea incidences were higher with Tac/MMF (P < .05). The incidence of any antidiabetic treatment for >30 consecutive days in previously nondiabetic patients was 17.8%, Tac/SRL, and 24.8%, Tac/MMF. Ev

Název v anglickém jazyce

Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation

Popis výsledku anglicky

In a multicenter trial, renal transplant recipients were randomized to tacrolimus with fixed-dose sirolimus (Tac/SRL, N = 318) or tacrolimus with MMF (Tac/MMF, N = 316). Targeted tacrolimus trough levels were lower in the Tac/SRL group after day 14. Theprimary endpoint was renal function at 6 months using creatinine clearance (Cockcroft-Gault) and was comparable at 66.4?mL/min (SE 1.4) with Tac/SRL and at 65.2mL/min (SE 1.3) with Tac/MMF (completers). Biopsy-confirmed acute rejection was 15.1% (Tac/SRL) and 12.3% (Tac/MMF). In both groups, graft survival was 93% and patient survival was 99.0%. Premature withdrawal due to an adverse event was twice as high in the Tac/SRL group, 15.1% versus 6.3%. Hypercholesterolemia incidence was higher with Tac/SRL (P < .05) while CMV, leukopenia, and diarrhea incidences were higher with Tac/MMF (P < .05). The incidence of any antidiabetic treatment for >30 consecutive days in previously nondiabetic patients was 17.8%, Tac/SRL, and 24.8%, Tac/MMF. Ev

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of transplantation

ISSN

2090-0007

e-ISSN

—

Svazek periodika

2010

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1-10

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—